We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Boehringer Ingelheim Expands Capabilities in Biopharmaceutical Process Science
News

Boehringer Ingelheim Expands Capabilities in Biopharmaceutical Process Science

Boehringer Ingelheim Expands Capabilities in Biopharmaceutical Process Science
News

Boehringer Ingelheim Expands Capabilities in Biopharmaceutical Process Science

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Boehringer Ingelheim Expands Capabilities in Biopharmaceutical Process Science"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Boehringer Ingelheim has expanded its biopharmaceutical development and manufacturing capabilities at its cell culture and microbial sites in Biberach, Germany and in Vienna, Austria.

These expansions will enhance cell line development with the proprietary BI-HEX® high expression system and microbial strain as well as process development services for the contract manufacturing business.

The investment of approximately 17 million Euros included the expansion of Boehringer Ingelheim’s current GMP (good manufacturing practice) cell banking, process science, cell line development and quality laboratories, all equipped with the latest technologies.

With this new set up Boehringer Ingelheim can offer highly competitive services including it’s newly established 'Lean to Clinic' program for monoclonal antibody projects, in which drug substance may be delivered after only 13 months for clinical studies.

In the microbial business the increased resources will strengthen Boehringer Ingelheim’s proprietary technologies like the high yield and high purity pDNA platform and will also support the technology collaborations with Pfenex Inc on the Pseudomonas technology and with VTU Technology on the Pichia expression technology.

"The expansion has been taylor-suited to fully meet our customer demands in cell culture and microbial process science, especially for our rapidly expanding pre-clinical project portfolio with biotech companies", commented Dr. Dorothee Ambrosius, Senior Vice President Biopharmaceuticals Global Process Science at Boehringer Ingelheim.

Dr. Ambrosius continued, "This is another milestone within our contract manufacturing strategy securing technology leadership and towards increased flexibility and customer orientation."

Advertisement